Additionally, TP53 and KRAS mutations co-occur in lung adenocarcinoma and pancreatic ductal adenocarcinoma but are mutually exclusive in uterine corpus endometrial carcinoma and cholangiocarcinoma (Supplementary Data 2). The gene discussed is KRAS; the disease is pancreatic ductal adenocarcinoma.